14.68

2.13% -0.32

Bicycle Therapeutics Plc Adr (BCYC)

Overview News Price History Option Chain Financials Discussions Forecast

Bicycle Therapeutics Plc Adr stock is traded at $14.68, with a volume of 343.09K. It is down -2.13% in the last 24 hours and down -27.90% over the past month. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Previous Close:

$15.00

Open:

$15

24h Volume:

343.09K

Relative Volume:

0.74

Market Cap:

$1.01B

Revenue:

$26.98M

Net Income/Loss:

$-180.66M

P/E Ratio:

-3.1368

EPS:

-4.68

Net Cash Flow:

$-63.56M

1W Performance:

+6.30%

1M Performance:

-27.90%

6M Performance:

-27.40%

1Y Performance:

-18.81%

1-Day Range:

$14.64

$15.30

1-Week Range:

$13.88

$17.04

52-Week Range:

$12.17

$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name

Bicycle Therapeutics Plc Adr

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

011441223261503

Address

BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE

Employee

284

Twitter

@Bicycle_tx

Next Earnings Date

2024-10-31

Latest SEC Filings

BCYC's Discussions on Twitter

Compare BCYC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCYC Bicycle Therapeutics Plc Adr	14.68	1.01B	26.98M	-180.66M	-63.56M	-5.13
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Equal-Weight
Sep-06-24	Initiated	RBC Capital Mkts	Outperform
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight
Jul-06-22	Resumed	Canaccord Genuity	Buy
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight
Dec-17-21	Initiated	SVB Leerink	Outperform
Dec-09-21	Initiated	Needham	Buy
Sep-30-21	Initiated	B. Riley Securities	Buy
Apr-20-21	Initiated	JMP Securities	Mkt Outperform
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy
Nov-14-19	Initiated	ROTH Capital	Buy
Sep-11-19	Upgrade	Goldman	Neutral → Buy
Jun-17-19	Initiated	Canaccord Genuity	Buy
Jun-17-19	Initiated	Goldman	Neutral
Jun-17-19	Initiated	Jefferies	Buy
Jun-17-19	Initiated	Piper Jaffray	Overweight

View All

Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News

Dec 19, 2024

Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India

Dec 19, 2024

Dec 14, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa

Dec 14, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com

Dec 14, 2024

Dec 09, 2024

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance

Dec 09, 2024

Nov 27, 2024

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance

Nov 27, 2024

Nov 25, 2024

Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance

Nov 25, 2024

Nov 21, 2024

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance

Nov 21, 2024

Nov 19, 2024

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance

Nov 15, 2024

Nov 13, 2024

Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India

Nov 13, 2024

Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com

Nov 13, 2024

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Yahoo Finance

Nov 13, 2024

Nov 02, 2024

Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 02, 2024

Oct 31, 2024

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance

Oct 31, 2024

Oct 28, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India

Oct 28, 2024

Oct 24, 2024

Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com

Oct 24, 2024

Oct 23, 2024

Bicycle Therapeutics spotlights cancer treatment targets - Investing.com

Oct 23, 2024

Oct 21, 2024

Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance

Oct 21, 2024

Oct 19, 2024

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN

Oct 19, 2024

Oct 14, 2024

A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily

Oct 14, 2024

Oct 10, 2024

BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 10, 2024

Oct 08, 2024

Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily

Oct 08, 2024